Use of daratumumab in high risk multiple myeloma: A meta‐analysis
Abstract Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley
2020-07-01
|
| Serija: | eJHaem |
| Teme: | |
| Online pristup: | https://doi.org/10.1002/jha2.47 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|